



SKINOSIVE

While innovation in the sun protection market has focused primarily on marketing and sensory appeal over the past twenty years, Skinosive has developed a breakthrough biotechnology platform based on skin bioadhesion. Its proprietary technology enables UV filters to be permanently anchored to the skin's surface for up to 8 hours, without lateral spread or skin penetration, thereby addressing major challenges related to long-lasting efficacy, safety, and ease of use.

The performance of this technology has been clinically demonstrated:

1. unique retention on the skin's surface for up to 8 hours, providing long-lasting UV protection after a single application
2. no skin penetration, confirmed by confocal Raman imaging,
3. an excellent safety profile, validated in humans.

Skinosive is developing a technology platform that structured a portfolio of four bio-adhesive UV filters covering the entire UVA and UVB spectrum, designed to be combined to bring to market the first long-lasting SPF50+ product with no systemic exposure.

The company enjoys international scientific and industrial recognition: a recent academic publication in the Journal of Investigative Dermatology (Bertrand et al., 2026), multiple presentations at major conferences in the United States and Europe, and the Rising Star Award at IN COSMETICS GLOBAL 2024.

Skinosive is backed by:

1. an experienced management team with backgrounds in the pharmaceutical and dermo-cosmetic industries
2. a leading founding shareholder behind several landmark successes in European biotech
3. a world-class international scientific advisory board,
4. a robust and extensive intellectual property portfolio, with nine patent families protecting the technology through 2046.

Skinosive embodies a dermo-cosmetic biotech company with high potential:

1. clinically validated breakthrough innovation,
2. a massive \$12 billion market, currently lacking innovation and awaiting safer, more effective solutions
3. a clear regulatory and commercial trajectory
4. prospects for value creation in the short and medium term.

Contacts:

Headquarters : 12-14 Rue Jean Antoine de Baïf, 75013 Paris

Laboratoires : 60 Avenue André Roussin, 13016 Marseille

CEO : Benoit Canolle, benoit.canolle@skinosive.com

BD Dir: Agnès Menut, agnes.menut@skinosive.com

SKINOSIVE

SAS au capital de 695 166 €

R.C.S. PARIS 834 150 351 – SIREN 834 150 351
12/14 rue Jean Antoine de Baïf 75013 PARIS